TherapeuticsMD, Inc. / Fundamentals
Income statement
- Net revenue
€2.21M - Cost of goods sold
€197.64K - Gross profit
€2.04M - SG&A expenses
€4.16M - R&D expenses
€0.00 - EBITDA
-€1.19M - D&A
€333.99K - EBIT
-€2.37M - Interest expenses
€6.04K - EBT
-€523.86K - Tax expenses
-€59.55K - Net income
-€396.13K
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€757.75K - Changes in working capital
€554.93K - Operating cash flow
€885.48K - Capex
€0.00 - Other investing cash flow
€0.00 - Net investing cash flow
€0.00 - Total cash dividends paid
€0.00 - Issuance of common stock
€0.00 - Debt repayment
€0.00 - Other financing cash flow
€0.00 - Net financing cash flow
€0.00 - Foreign exchange effects
€0.00 - Net change in cash
€722.36K - Cash at end of period
€5.24M - Free cash flow
€885.48K
Balance sheet
- Cash and cash equivalents
€5.24M - Cash and short-term investments
€5.24M - Total receivables
€3.23M - Inventory
€0.00 - Other current assets
€3.15M - Total current assets
€11.62M - Property, plant & equipment
€4.95M - Goodwill
€0.00 - Intangible assets
€3.49M - Long-term investments
€12.81M - Other non-current assets
€369.38K - Total non-current assets
€21.61M - Total assets
€33.23M - Accounts payable
€302.06K - Short-term debt
€764.65K - Other current liabilities
€2.96M - Total current liabilities
€4.02M - Long-term debt
€9.87M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€718.05K - Total non-current liabilities
€5.65M - Total liabilities
€9.68M - Common stock
€9.49K - Retained earnings
-€821.54M - Other equity
€0.00 - Total equity
€23.55M - Total liabilities and shareholders' equity
€33.23M
Company information
- Market capitalization
€11.06M - Employees
1 - Enterprise Value
€14.10M
Company ratios
- Gross margin
-
92.3% Much better than peer group: 33.5% - EBITDA margin
-
-53.8% Much worse than peer group: 993,599.8% - EBIT margin
-
-107.2% Much worse than peer group: 935,664.5% - EBT margin
-
-23.7% Much worse than peer group: 994,040.1% - Net margin
-
-17.9% Much worse than peer group: 901,249.3% - ROE
-
-1.7% Much better than peer group: -26.6% - ROA
-
-1.2% Much better than peer group: -51.7% - Asset turnover
-
6.6% Much worse than peer group: 51.9% - FCF margin
-
40.1% Much worse than peer group: 699,074.9% - FCF yield
8.0% - Efficiency ratio
153.8% - Net sales per employee
-
€2.21M - Net income per employee
-
-€396.13K